Results 161 to 170 of about 62,516 (342)

Channeled fiberoptic for vocal cord polyp excision under spontaneous respiration using intravenous anesthesia and hi-flow nasal oxygen (STRIVE-Hi) technique: A case report and review of the literature

, 2020
Abhishek Menon, Dina Emam, Olfa Al-Mannai, Nabil A. Shallik, Muayad M. Radi Al-Khafaji   +4 more
openalex   +1 more source

Multiple genetic variations of chronic rhinosinusitis with nasal polyps are associated with respiratory parameters in men with obstructive sleep apnea [PDF]

, 2021
Qianqian Zhang, Xiaoting Wang, Xiangyu Cheng, Xiaolin Wu, Yunhai Feng, Huajun Xu, Huaming Zhu, Hongliang Yi, Weitian Zhang, Xinyi Li, Haibo Ye   +10 more
openalex   +1 more source

An Algorithm for the Diagnosis and Management of Severe Asthma in Children and Adolescents

Allergy, EarlyView.
Eckard Hamelmann, Bianca Schaub, Susanne Lau, Leonard B. Bacharier   +3 more
wiley   +1 more source

Early and Sustained Asthma Control and Remission in Real‐World Patients With Severe Eosinophilic Asthma Treated With Benralizumab: XALOC‐2

Clinical &Experimental Allergy, EarlyView.
Real‐world patients with severe eosinophilic asthma treated with benralizumab showed early and sustained improvements in symptoms. Clinically meaningful improvements began as early as one week after benralizumab initiation, regardless of previous biologic use, and further improved over the following year.
Erika Penz, Thomas Rothe, Lieven Dupont, Trung N. Tran, Andrew Menzies‐Gow, Anat Shavit, David Cohen, Tanja Plate, Sheena Kayaniyil, An Herreman, Claudio Schuoler, Benjamin Emmanuel, Marek Lommatzsch   +12 more
wiley   +1 more source

The IL-4 mediated regulation of periostin in epithelial cells in chronic rhinosinusitis with nasal polyps

, 2022
Karla Hegener, Jonghui Kim, IngaMarteCharlott Seuthe, Jürgen Knobloch, JonasJae-Hyun Park   +4 more
openalex   +1 more source

Dupilumab Dampens Mucosal Type 2 Response During Acetylsalicylic Acid Challenge in N‐ERD Patients

Clinical &Experimental Allergy, EarlyView.
Dupilumab therapy reduced elevated type 2 cytokine responses post‐ASA provocation in N‐ERD patients, independent of ASA tolerance, and revealed novel mechanistic insights by modulating acute type 2 immunity. Transcriptomic analysis showed concurrent downregulation of lipid and peroxisome pathways during ASA challenge in N‐ERD patients after 24 weeks of
Julia Eckl‐Dorna, Christina Morgenstern, Katharina Poglitsch, Tamara Arnoldner, Katharina Gangl, Tina J. Bartosik, Nicholas J. Campion, Aldine Tu, Victoria Stanek, Sven Schneider, Christine Bangert   +10 more
wiley   +1 more source

Activation Of TLR4 Induces VEGF Expression Via Akt Pathway In Nasal Polyps [PDF]

, 2014
Jung‐Sun Cho, Ju-Hyung Kang, In-Hye Han, Ji‐Young Um, Il‐Ho Park, Heung‐Man Lee   +5 more
openalex   +1 more source

Modifiable Risk Factors for Symptom Burden in Chronic Rhinosinusitis With Nasal Polyps: The Role of Obesity and Sleep Apnoea

Clinical Otolaryngology, EarlyView.
ABSTRACT Objective To identify sociodemographic and clinical predictors of symptom severity and quality of life (QoL) impairment in patients with chronic rhinosinusitis with nasal polyps (CRSwNP), diagnosed according to the latest EPOS 2020 criteria. Study Design Cross‐sectional analytical study.
Javier Modesto García‐Fernández, María Soledad Sánchez‐Torices, María Pilar Gómez‐Gallego, Miguel Ángel Feliz‐Fernández, María Alharilla Montilla‐Ibáñez, Rafael Lomas‐Vega   +5 more
wiley   +1 more source

Dupilumab Treatment Improves Sense of Smell in Patients With Chronic Rhinosinusitis With Nasal Polyps – Pooled Results From the SINUS-24 and SINUS-52 Phase 3 Trials [PDF]

, 2020
Joaquim Mullol, Joseph K. Han, John V. Bosso, Leda Mannent, Nikhil Amin, Seong Cho, Claus Bachert   +6 more
openalex   +1 more source

Incidence, Risk Factors, and Management of Conjunctivitis in Atopic Dermatitis Patients Treated With Dupilumab or Tralokinumab: Results From a Multicenter, Observational, Retrospective Study

International Journal of Dermatology, EarlyView.
ABSTRACT Background Conjunctivitis is among the most frequent adverse events (AEs) emerged in clinical trials for all biologic drugs approved for atopic dermatitis (AD). However, real‐world comparative data on the incidence, risk factors, and management of conjunctivitis remain limited.
Luca Potestio, Cataldo Patruno, Marika Del Gaudio, Michela Ortoncelli, Simone Ribero, Francesca Barei, Silvia Mariel Ferrucci, Laura Bonzano, Ilaria Trave, Mario Bruno Guanti, Carlotta Gurioli, Bianca Maria Piraccini, Niccolò Gori, Elena Ippoliti, Ketty Peris, Laura Grigolato, Mariateresa Rossi, Caterina Foti, Paolo Romita, Benedetta Tirone, Eustachio Nettis, Maria Esposito, Maria Concetta Fargnoli, Lina Maria Magnanimi, Elena Pezzolo, Katharina Hansel, Luca Stingeni, Rosanna Satta, Maria Mariano, Flavia Pigliacelli, Flavia Manzo Margiotta, Marco Romanelli, Ruggero Cascio Ingurgio, Antonio Costanzo, Alessandra Narcisi, Monica Corazza, Emiliano Antiga, Pietro Morrone, Pietro Rubegni, Laura Calabrese, Laura Lazzeri, Giovanni Rubegni, Fabrizio Guarneri, Nicola Zerbinati, Andrea Carugno, Rosa Valentina Puca, Oriele Sarno, Claudio Marasca, Emanuela Martina, Francesca di Vico, Maddalena Napolitano   +50 more
wiley   +1 more source